Drug Database
LA

lamotrigine orally disintegrating tablet (lamotrigine ODT / lamictal ODT / EUR1048)

✓ Approved

Adare Pharma Solutions · SCN1A · Small Molecule

What is lamotrigine orally disintegrating tablet?

lamotrigine orally disintegrating tablet is a small molecule developed by Adare Pharma Solutions. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Nameslamotrigine ODT, lamictal ODT, EUR1048
CompanyAdare Pharma Solutions
Drug ClassSmall Molecule
Molecular TargetSCN1A, SCN2A, SCN3A
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

lamotrigine orally disintegrating tablet acts on 3 molecular targets:

SCN1Asodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3)
SCN2Asodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS)
SCN3Asodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

lamotrigine orally disintegrating tablet is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Nervous system disordersGeneralised tonic-clonic seizure✓ Approved
Nervous system disordersLennox-Gastaut syndrome✓ Approved
Psychiatric disordersBipolar disorder✓ Approved
Nervous system disordersPartial seizures✓ Approved

Related Research Articles

PubMedBiology2026-10-16

Remote Body Temperature Monitoring in Infectious Diseases: Pilot Studies in Different Artiodactyla Models.

Konold Timm T, Wallworth Sarah S, Roccia Christina C, Jarman Jenny J et al.

Thermal microchips are increasingly used in animals as an alternative to rectal temperature measurements because handling is not required. These pilot studies aimed to determine the usefulness of orally administered thermal microchips in infectious disease studies of artiodactyla species when a temperature increase was expected. Thermal microchips were administered subcutaneously to two groups of seven alpacas infected with influenza C and D virus respectively and three alpacas serving as non-challenged controls and orally to one alpaca in each group. Three sheep exposed to border disease virus and 12 cattle with experimental bovine tuberculosis when subjected to tuberculin skin testing were also given microchips orally. A temperature rise was observed in microchips and rectal temperatures around the same time in one alpaca and one sheep following infection, but was also recorded in orally administered microchips earlier during the night. A temperature rise was detected in all skin test-positive cattle except for one calf with a negative skin test and the least visible granulomatous lesions in the chest. Orally administered thermal microchips are a promising addition to rectal temperatures to determine body temperature changes in real time regardless of the time of day, to study physiological responses to infectious or immunogenic agents and possibly refine humane end-points in experimental studies. Factors to consider are bolus size, battery power and network connectivity to prevent data gaps (seen in alpaca and sheep) or excretion via feces (in sheep).

PubMedInternational journal of molecular sciences2026-10-16

CYP2C9 Pharmacogenetic Variants and Adverse Drug Reactions to Antiseizure Medications: An Exploratory Analysis in the Venezuelan Andes.

Morales-Ortiz Alexis A, Quiñones Luis Abel LA, Rondón-Simancas Sol Betzabeth SB, Paredes Gustavo G et al.

Epilepsy is a chronic neurological disorder with a high global prevalence. In Venezuela, the limited availability of epidemiological and pharmacogenetic data represents an important public health challenge. Antiseizure medications (ASMs) are frequently associated with adverse drug reactions (ADRs), which may be influenced by genetic variability in drug-metabolising enzymes. This study evaluated the association between the CYP2C9*2 and CYP2C9*3 variants and the occurrence of ADRs in patients receiving anticonvulsant treatment in the Venezuelan Andes. An observational, analytical, cross-sectional study was conducted in 72 patients. Genomic DNA was extracted from venous blood, and CYP2C9 genotypes were determined by real-time PCR using TaqMan® probes. The frequencies of the CYP2C9*2 and CYP2C9*3 alleles were 0.15 and 0.06, respectively. The metaboliser phenotype was significantly associated with the presence of ADRs. The risk of ADRs was elevated in the intermediate/poor metaboliser group (IM/PM: OR = 17.45; 95%CI: 5.09-76.56; p < 0.001) and in patients on polypharmacy (OR = 15.03; 95%CI: 2.73-157.37; p = 0.001), although this latter estimate showed marked imprecision due to the width of its interval. Consistent with this, the ADR rate was higher in PM (100%; 3/3) and IM (84.2%; 16/19) than in normal group (20.9%; 9/43). In the monotherapy subgroup, the type of ASM showed no association with the occurrence of ADR (p = 0.741). Among normal metabolisers receiving polytherapy, regimens containing valproic acid were associated with the highest proportion of ADRs, with dual therapy including lamotrigine accounting for 28.57%. Although the overall analysis indicated differences in ADR occurrence according to polytherapy regimen (p = 0.043), the limited sample size restricts the strength of these findings. These results suggest that CYP2C9*2 and CYP2C9*3 variants may contribute to variability in the safety of anticonvulsant treatment among patients from the Venezuelan Andes by influencing CYP2C9 metaboliser phenotypes, and consequently, drug pharmacokinetics. Further studies in larger and more representative Venezuelan populations are warranted to validate these findings.

PubMedBMC chemistry2026-10-16

A green square-wave voltammetric method for albendazole determination at a glassy carbon electrode: first use of ethanol as an environmentally friendly solvent.

Sofu Ümran Ü, Telli Sude S, Üstün Zehra Z, Demiralay Ebru Çubuk EÇ

A simple, sensitive square-wave voltammetric method was developed for the determination of albendazole at an unmodified glassy carbon electrode, employing ethanol for the first time as a green co-solvent in the electroanalytical assay of this compound. Optimum conditions were established as Britton-Robinson buffer (pH 2.0) containing 20% (v/v) ethanol. The oxidation of albendazole was found to be a diffusion-controlled, proton-coupled electron transfer process, based on scan rate studies. Under optimized conditions, the peak current increased linearly with albendazole concentration over the range 0.06-20 µM, with a detection limit of 21.3 nM. The method was validated according to ICH Q2(R2) guidelines and successfully applied to the determination of albendazole in a commercial tablet formulation, giving satisfactory recovery, precision, and accuracy. The developed method demonstrated good selectivity with a tolerance limit of ±2.52% in the presence of potential interfering agents commonly found in human body fluids and pharmaceutical formulations. The suitability of the developed method for green and white analytical chemistry approaches was evaluated using various tools. This study is the first to report the qualitative and quantitative determination of albendazole within an environmentally friendly analytical framework, using potentially non-toxic solvents and energy and reducing waste generation.

PubMedPolymers2026-10-16

Preparation and Characterization of Immediate-Release Tablets Containing Calcium Lactate Recovered from Chemically Recycled Poly(lactic acid) 3D Printing Filaments.

Attallah Olivia A OA, Brandao Dario D, Tran Jacqueline J, Rivera Irvin I et al.

Polylactic acid (PLA) is one type of biodegradable plastic that can replace single-use plastic. Nevertheless, it still poses the problem of accumulation in the environment due to the slow biodegradation rate. Developing simple yet effective methods for PLA recycling and upcycling can pave the way for a circular economy and help partially solve the plastic pollution problem. In the present work, PLA filaments of different colors were chemically recycled in alkaline solutions of C1-C3 primary alcohols under mild experimental conditions (75 °C for 30 min, 1 atm). The effect of various process parameters such as depolymerization solvent media and PLA pigmentation on the percentage of PLA depolymerization and Ca lactate monomer yield was studied. PLA filament size was also investigated as a factor affecting the kinetics of PLA depolymerization. As a monomer, Ca lactate was evaluated by different characterization techniques including Fourier transform infrared spectroscopy, Nuclear Magnetic Resonance, and Atomic Absorption Spectroscopy. In addition, the powder quality was tested against US Pharmacopeia standards for acidity, heavy metal presence, hydration state, and calcium content. The recycled Ca lactate was formulated with other ingredients into Ca lactate tablets via direct compression to serve as a calcium source for preventing and treating calcium deficiencies. The tablet characteristics were compared against commercially available Ca supplements with respect to shape consistency, uniformity of calcium loading, immediate release, and cytotoxicity. The obtained findings suggest that there exists a viable, environmentally friendly avenue for utilizing PLA recycling products in the development of compounds with potential applications in the pharmaceutical domain.

PubMedAnimals : an open access journal from MDPI2026-10-16

Oral Mosapride Attenuates Gastrointestinal Dysmotility During Experimental Endotoxemia in Horses: A Randomized, Blinded Crossover Study.

Varela Diego Duarte DD, Rosa Ana Carolina Ribeiro ACR, Sousa Lara Nunes LN, Luvison Eduarda Zancanaro EZ et al.

Endotoxemia is a major contributor to gastrointestinal hypomotility and postoperative ileus in horses. This study investigated whether oral mosapride retained prokinetic activity during acute lipopolysaccharide (LPS)-induced endotoxemia. Seven healthy adult horses were enrolled in a randomized, blinded, three-period crossover trial and received LPS alone, mosapride alone (MOSA), or LPS plus mosapride (LPS + MOSA), with a 14-day washout interval between periods. Mosapride was administered orally at 2 mg/kg, whereas endotoxemia was induced by an intravenous infusion of Escherichia coli O55:B5 LPS (0.03 µg/kg) over 30 min. Clinical variables, hematologic parameters, abdominal auscultation, and transabdominal ultrasonography were assessed from baseline to 6 h. LPS induced tachycardia, hyperthermia, leukocyte alterations, marked gastrointestinal hypomotility, gastric distension, and increased intestinal wall thickness. Mosapride alone increased gastrointestinal motility without clinically relevant abnormalities. During endotoxemia, mosapride partially restored gastrointestinal motility, reduced intestinal wall thickening and gastric distension, and was associated with a less pronounced hematologic inflammatory response than LPS alone. These findings indicate that oral mosapride retains clinically relevant prokinetic activity during acute experimental endotoxemia and support further investigation of its use as an adjunctive treatment for inflammation-associated gastrointestinal hypomotility in horses.

PubMedMolecules (Basel, Switzerland)2026-10-16

Polydeoxyribonucleotide Promotes Longitudinal Bone Growth Through the Hepatic JAK2-STAT5/IGF-1 Axis Involving A2A Receptor Signaling.

Jeong Kyung-Min KM, Choi Yu-Jin YJ, Yang Seong-Been SB, Kweon Minson M et al.

Longitudinal bone growth is primarily regulated by the growth hormone (GH)-insulin-like growth factor-1 (IGF-1) axis. However, non-hormonal and orally administered strategies for promoting longitudinal growth remain limited. Here, we investigated the effects and mechanisms of polydeoxyribonucleotide (PDRN) on longitudinal bone growth in vitro and in vivo. In HepG2 cells, PDRN significantly increased IGF-1 mRNA expression and JAK2 and STAT5 phosphorylation without affecting cell viability. Pretreatment with ZM241385, a selective adenosine A2A receptor (A2AR) antagonist, significantly attenuated these responses, supporting the involvement of A2AR signaling. In mice, oral PDRN for 5 weeks significantly increased body length gain, growth plate thickness, and hepatic JAK2/STAT5 activation, elevating serum IGF-1 levels without altering GH levels or systemic toxicity markers. Quantitative micro-computed tomography analysis demonstrated improved trabecular and cortical bone microarchitecture with reduced porosity. Furthermore, PDRN modulated bone remodeling-related responses by suppressing lipopolysaccharide-induced osteoclastogenic marker expression in RAW 264.7 cells and enhancing osteogenic marker expression while downregulating RANKL in MC3T3-E1 cells. Overall, oral PDRN promotes longitudinal bone growth and improves microarchitecture via increased hepatic IGF-1 signaling and altered bone remodeling-related gene expression, supporting its potential as an oral candidate for skeletal growth.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about lamotrigine orally disintegrating tablet